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Abstract Over half of patients with human immun-
odeficiency virus (HIV) experience diarrhea that con-
tributes negatively to quality of life and adherence to
antiretroviral therapy (ART). Opportunistic infectious
agents that cause diarrhea in patients with HIV span the
array of protozoa, fungi, viruses, and bacteria. With global
use of ART, the incidence of diarrhea because of oppor-
tunistic infections has decreased; however, the incidence of
noninfectious diarrhea has increased. The etiology of
noninfectious diarrhea in patients with HIV is multifacto-
rial and includes ART-associated diarrhea and gastroin-
testinal damage related to HIV infection (i.e., HIV
enteropathy). A basic algorithm for the diagnosis of diar-
rhea in patients with HIV includes physical examination, a
review of medical history, assessment of HIV viral load
and CD4? T cell count, stool microbiologic assessment,
and endoscopic evaluation, if needed. For patients with
negative diagnostic results, the diagnosis of noninfectious
diarrhea may be considered. Pharmacologic options for the
treatment of noninfectious diarrhea are primarily support-
ive; however, the use of many unapproved agents is based
on unstudied and anecdotal information. In addition, these
agents can be associated with treatment-limiting adverse
events (AEs), such as drug–drug interactions with ART
regimens, abuse liability, and additional gastrointestinal
AEs. Currently, crofelemer, an antisecretory agent, is the
only therapy approved in the USA for the symptomatic
relief of noninfectious diarrhea in patients with HIV on
ART.
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Introduction
Advances in the treatment of human immunodeficiency virus
(HIV) and acquired immunodeficiency syndrome (AIDS)
have transformed this disease into a chronic illness [1]. As a
result, individuals with HIV have a longer life expectancy
[2]. When HIV is treated early and aggressively, life ex-
pectancy approaches that of uninfected individuals [3, 4].
According to the Centers for Disease Control and Prevention
(CDC), the annual incidence of HIV has remained stable
during the past 10 years [2]. In 2010, the prevalence of HIV
in individuals aged over 13 years was estimated to be about
1,148,200 [5]. Although this number illustrates a dramatic
increase in the prevalence of HIV since 1996, it is largely due
to the decreased mortality rate associated with the advent of
antiretroviral therapy (ART) [2].
Because most cases of diarrhea in the pre-ART era were
due to infectious pathogens, it was widely believed that
successful treatment would reduce, or even solve, this
problem [6, 7]. Although ART has improved the survival
and quality of life of patients with HIV, and even decreased
the incidence of diarrhea in this population, diarrhea re-
mains a common complaint among these patients and
continues to negatively impact the quality of life [6–9].
Furthermore, while the burden of diarrhea in the HIV-in-
fected population remains high, the causes of diarrhea have
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shifted toward noninfectious etiologies [6, 7]. In one survey,
*60 % of patients receiving ART reported having the
symptom of diarrhea in the previous month [10]; clinical
trial data would suggest that up to 19 % of these events may
have been due to the effects of ART itself [11]. In support of
this assertion, US historical data of HIV-infected patients
with CD4? T cell counts \200 cells/mm3 were investi-
gated and demonstrated a decline in infectious diarrhea
from 53 to 13 % over 3 years (1995–1997); this correlated
with the introduction of ART around 1995 [6]. During that
same period, the percentage of patients with noninfectious
diarrhea increased from 32 to 71 % [6]. A similar trend in
etiologic differences has been observed in other countries
for patients taking ART versus those not taking ART [12].
This review explores some explanations for the continued
burden of diarrhea among patients with HIV, discusses the
diagnostic workup, and provides guidance on how HIV-
associated noninfectious diarrhea should be treated.
Pathophysiology
HIV Infection of the Gastrointestinal Tract
Gut-associated lymphoid tissue (GALT) is the largest col-
lection of lymphoid tissue in the human body [13]. The
gastrointestinal (GI) tract is regularly exposed to a complex
and diverse assortment of antigens from both microbial and
dietary sources [14]. As a result, naı¨veB andT cells of the gut
are constantly interacting with antigens that induce their
maturation into plasma cells and memory T cells, respec-
tively. This persistent stimulation of the immune system
leads to a baseline inflammatory state that encourages the
production of chemokines and adhesion molecules, which
mediate the movement of lymphocytes into the mucosal
tissues [13, 15]. The GI tract is targeted during all phases of
HIV infection, but the effects ofHIVon themucosal immune
system are most apparent in the acute infection period. Data
from simian models with simian immunodeficiency virus
[16] and frompatientswithHIV [13, 17, 18] show that within
weeks of infection, the vast majority of mucosal lamina
propria CD4? lymphocytes are depleted. This depletion
occurs well before any decrease in CD4? T cells is seen in
the periphery and likely reflects the greater expression of the
CC chemokine receptor type 5 (CCR5), which functions as
the primary coreceptor for the majority of infective HIV
strains, onmucosal CD4?T cells [19]. The expression of the
chemokine receptor on these cells supports the entry of the
virus, but their state of physiologic activation is responsible
for enhanced HIV replication in the mucosal compartment
and subsequent mucosal CD4? T cell depletion. Further,
despite the use of potent antiretroviral medications, HIV
persists within GALT lymphocytes, even after repletion of
CD4? T cells in the periphery [20]. Thus, in patients with
chronic HIV infection, the mucosal environment contains a
paucity of CD4? T cells but is overpopulated with CD8? T
cells and B cells, giving the wrong impression of a healthy
mucosal environment at the microscopic level [21].
The etiology of diarrhea in HIV-infected patients can be
divided into two major categories: noninfectious and in-
fectious. As treatment of HIV has improved, the increase in
peripheral CD4? T cell counts has resulted in a decline in
the risk of infection and associated diarrhea (Fig. 1) [22].
Indicative of this shift, noninfectious etiologies of diarrhea
have now surpassed infectious causes [6]. Noninfectious
diarrhea is defined as pathogen-negative diarrhea and in-
cludes ART-associated diarrhea, GI damage related to HIV
infection (i.e., HIV enteropathy), and many causes mir-
roring those seen in gender- and age-matched patients
without HIV infection.
Noninfectious Etiologies of Diarrhea
HIV Enteropathy
HIV enteropathy is an idiopathic form of diarrhea observed
in patients with HIV in the absence of an infectious source
with characteristic histologic features (Table 1) [8, 23–25].
While the exact mechanisms by which these changes occur
in the GI tract are unclear, HIV has been postulated to alter
signaling and cellular structure, which may lead to archi-
tectural distortion [23]. Several studies have demonstrated
crypt epithelial proliferation in response to HIV infection,
leading to increased crypt height, subsequent crypt cell
encroachment onto villi, and relative decreased villous
height resulting in diarrhea and malabsorption [26, 27]. A
study by Keating and colleagues that investigated
monosaccharide absorption in patients with HIV and AIDS
demonstrated that patients with diarrhea had significant
malabsorption of all monosaccharides tested [28]. Evi-
dence of malabsorption was reported in patients with both
pathogen-negative (n = 7) and pathogen-positive (n = 27)
diarrhea, suggesting that malabsorption may be involved in
HIV enteropathy, as well as in pathogen-induced diarrhea.
Other hypotheses for the mechanism of HIV enteropathy
include decreased transepithelial electrical resistance, de-
creased sodium-dependent glucose absorption, and in-
creased intercellular permeability inHIV-infected cells [29].
In vitro studies have demonstrated that gp120, an envelope
protein of HIV, induces microtubule disruption, decreases
epithelial resistance, and promotes calcium signaling within
the cell to affect these cytopathic changes [29, 30]. However,
there was no effect of gp120 on chloride secretion.
HIV enteropathy may occur at all stages of HIV infec-
tion, from acute HIV to advanced AIDS [23]. Data suggest
that HIV may be capable of infecting mucosal epithelial
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cells, resulting in direct effects on epithelial cell function
[31]. Further, microscopic inflammation may be
mechanistically involved in HIV enteropathy [23]. While
HIV rapidly and severely depletes mucosal T cells, the
total mucosal T cell population remains largely unchanged
[21]. This reflects greater mucosal infiltration by activated
CD8? T cells. These cells are primed to produce proin-
flammatory cytokines and chemokines, which may directly
Fig. 1 Common causes of
diarrhea at different stages of
HIV infection and treatment.
The shaded boxes indicate
causes of diarrhea at different
stages of HIV infection based
on CD4? T cell count. The
impact of starting ART on
CD4? T cell counts is depicted






Reprinted with permission from
[22]
Table 1 Idiopathic diarrhea in patients with HIV
Condition Clinical presentation/definition
HIV enteropathy [23] May be associated with
GI inflammation





Damage to the GI epithelium, including
Villous atrophy, crypt hyperplasia, and villous blunting
Irritable bowel syndrome
[24, 25]
Defined by the ACG as abdominal pain or associated with altered bowel habits over a period of C3 months
Defined by Rome III criteria as recurrent abdominal pain or discomfort for C3 days/month in the last 3 months
with symptom onset at C6 months before diagnosis and associated with C2 of the following:
Improvement with defecation
Onset associated with change in stool frequency
Onset associated with change in stool form
Functional diarrhea [24] Defined by Rome III criteria as C75 % of stools that are loose (mushy) and without pain for C3 months with
symptom onset C6 months before diagnosis
Reprinted with permission from [8]
ACG American College of Gastroenterology, GI gastrointestinal, HIV human immunodeficiency virus
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damage the mucosal barrier, resulting in decreased
transepithelial resistance and diarrhea [21, 23]. This has
been shown to lead to malabsorption of vitamin B12, bile
acid, and monosaccharides; thus, HIV enteropathy can also
be more specifically defined by its physiologic effect on
small bowel function [23, 28].
ART-Associated Diarrhea
While diarrhea is an adverse effect of ART, protease in-
hibitors seem to be most strongly associated with diarrhea
(Table 2) [32]. In mouse models, protease inhibitors and
reverse transcriptase inhibitors were found to significantly
increase water and electrolyte secretion into the intestinal
lumen in vivo [33]. Rufo and colleagues demonstrated that
protease inhibitors in general and nelfinavir in particular
potentiate signaling through muscarinic- and calcium-de-
pendent receptors of intestinal cells, resulting in increased
chloride secretion into the lumen [34]. This study also
showed that sodium and chloride concentrations in stool
samples from patients with HIV taking nelfinavir were
elevated, consistent with secretory diarrhea. In an in vitro
study, Bode and colleagues found that protease inhibitors
induced apoptosis of human intestinal epithelium, com-
promising barrier function in the cells and thereby in-
creasing water secretion in the gut lumen [35]. Wu and
colleagues also investigated the mechanism by which pro-
tease inhibitors cause diarrhea and found that lopinavir and
ritonavir (notably not amprenavir) induced endoplasmic
reticulum dysfunction in the intestinal epithelial cells [36].
When exposed to protease inhibitors, the cells were found to
have decreased alkaline phosphatase activity and thereby an
increase in unfolded proteins. The accumulation of defec-
tive proteins in the cytosol may persistently activate the
cell’s unfolded protein response, a specific signaling path-
way that aims to return the cell’s protein folding function
back to normal. If the levels of unfolded proteins do not
decrease, the cell may induce apoptosis.
Other Causes of Noninfectious Diarrhea
Functional bowel disorders, such as irritable bowel syn-
drome (IBS), are additional conditions that may present
with diarrhea [8]. In a survey conducted in a Veterans
Affairs outpatient setting, IBS was more common in HIV-
positive patients compared with HIV-negative patients
[37]. Another cause of noninfectious diarrhea is small in-
testinal bacterial overgrowth (SIBO) [38], a condition in
which increased bacteria in the small intestine leads to
multiple GI symptoms, including abdominal bloating and
discomfort, diarrhea, and malabsorption [39]. This condi-
tion may be more common in those with anatomic abnor-
malities and motility disorders, but does not appear to be a
common cause of diarrhea in those with HIV [40].
Infectious Etiologies of Diarrhea
Given the multitude of differences in standard of living
among developed versus developing countries and differ-
ences in availability of care for patients with HIV, the
incidence and type of various diarrhea-associated infec-
tions in immunocompromised patients may vary substan-
tially by region [41, 42]. In addition, diarrhea experienced
by HIV-infected individuals can be caused by pathogens
that are unique to the HIV population or by pathogens that
cause diarrhea in the immunocompetent host [41, 43]. For
example, Salmonella, Shigella, Campylobacter, Escher-
ichia coli, and enterotropic viruses cause diarrhea in both
the immunocompetent and HIV-infected patients. In addi-
tion to these pathogens, patients with HIV who are pro-
foundly immunosuppressed, with a CD4? T cell count
\200 cells/mm3, are also susceptible to opportunistic in-
fections [44]. These opportunistic infections can be orga-
nized into four general categories of organisms: protozoa,
fungi, viruses, and bacteria (Table 3) [41, 45–48].
Protozoa
Cryptosporidiosis is caused by an intracellular pathogen,
Cryptosporidium [49]. Infection with Cryptosporidium
parvum is a common cause of diarrhea worldwide [45].
There is an estimated rate of *60,000 cases of
Table 2 Incidence of ART-associated diarrhea [32]










Nucleoside reverse transcriptase inhibitors






Adapted with permission from [32]
ART antiretroviral therapy
a Coformulated elvitegravir/cobicistat/emtricitabine/tenofovir
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cryptosporidial infection per year in the USA [50]; risk of
Cryptosporidium parvum infection is greater in developing
countries where there is poor sanitation [51–53]. It spreads
from person to person or via contaminated water (e.g.,
drinking water or recreational water sites) [54]. Although
the protozoa cause a mild, self-limited disease in im-
munocompetent individuals, it can manifest as severe,
watery diarrhea in HIV-infected patients and it can also
occasionally lead to a chronic infection [49]. In the pro-
foundly immunocompromised, Cryptosporidium parvum
can lead to a malabsorptive syndrome, severe dehydration,
and electrolyte derangements [49, 55].
Other protozoal infections that commonly affect patients
with HIV include Microsporidia, Isospora, Cyclospora,
and, less commonly, Toxoplasma and Leishmania species,
which like Cryptosporidium, affect the small intestine and
can lead to malabsorptive diarrheal illnesses [41].
Similarly, Giardia also is a very common protozoal
pathogen in both HIV-infected and immunocompetent
hosts and infects the small intestinal mucosa. Entamoeba
histolytica is a protozoal pathogen that can cause colitis in
the severely immunocompromised HIV-infected patient
and in rare and severe circumstances can lead to ulceration,
hematochezia, and even toxic megacolon.
Viruses
Cytomegalovirus (CMV) is the most common viral GI
pathogen in patients with AIDS [44]. CMV can affect the
entire GI tract but classically leads to diarrhea by causing
colitis characterized by rectal bleeding, abdominal pain, and
systemic signs such as fevers and weight loss [55]. HIV
infection itself can cause a diarrheal illness as described
below, and multiple other viruses have been implicated as
diarrheal pathogens, including adenovirus, coronavirus,
herpes simplex virus, rotavirus, and norovirus [44, 46].
Fungi
Rarely have fungi been reported to cause diarrhea in HIV-
infected patients [44]. Of the infections associated with
endemic fungi, histoplasmosis is the most common fungal
infection requiring hospitalization and can affect any part of
the GI tract, causing diarrhea, weight loss, and fever [56].
Bacteria
Mycobacterium avium complex (MAC) typically causes
diarrhea in patients with AIDS with profoundly suppressed
immune systems (i.e., CD4? T cell count\50 cells/mm3)
[44]. Symptoms are varied, but they usually reflect the
systemic nature of the disseminated infection and include
fever and weight loss [45]. MAC usually involves the small
intestine; however, it can affect the entire GI tract [55, 57].
Salmonella, Shigella, Campylobacter, and E coli are
bacterial infections of the GI tract that can present with
diarrhea [41]. They are usually spread through food and
water contamination. Patients with an impaired immune
system can become asymptomatic carriers of some patho-
gens (e.g., Shigella, Campylobacter). Clostridium difficile
should be investigated in patients who have recently taken
antibiotics [47]. It causes pseudomembranous colitis that
Table 3 Infectious causes of diarrhea in patients with HIV diagnosed by endoscopy or colonoscopy [41, 45–48]
Pathogen Endoscopy Colonoscopy
Bacteria Salmonella Salmonella, Shigella, Campylobacter
Enteropathogenic and enterotoxigenic
Escherichia coli (small intestine)
Enterohemorrhagic E coli, enteroinvasive E coli
Small intestine bacterial overgrowth Clostridium difficile
Mycobacterium avium complex Mycobacterium avium complex
Protozoa Cryptosporidia (small intestine) Cryptosporidia
Microsporidia (most often in proximal jejunum) Entamoeba histolytica




HSV HSV (rectum, sigmoid)
Adenovirus
Fungi Histoplasma (most commonly terminal ileum;
can affect any part of the GI tract)
Histoplasma (most commonly terminal ileum;
can affect any part of the GI tract)
Based on either appearance of mucosa in endoscopy/colonoscopy or mucosal biopsy
CMV cytomegalovirus, GI gastrointestinal, HIV human immunodeficiency virus, HSV herpes simplex virus
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can progress to toxic megacolon in severe infections.
Clostridium difficile is more common in patients with ad-
vanced AIDS (CD4? T cell count\50 cells/mm3). In one
study evaluating the incidence of bacterial diarrhea in pa-
tients with HIV, Clostridium difficile was the most common
identified culprit, accounting for 53.6 % of 1115 episodes
of diarrhea that had a bacterial pathogen isolated [36].
Overall, protozoa, fungi, MAC, and CMV GI infections
are usually seen only in patients with HIV and other im-
munocompromised patients [58]. As noted earlier, with
improved therapy, patients infected with HIV are less
prone to develop diarrhea due to infectious pathogens and
are more prone to noninfectious causes [48].
Diagnosis
The basic algorithm for the diagnosis and evaluation of diar-
rhea in patients with HIV is similar to the examination of
diarrhea in the immunocompetent host and starts with a thor-
ough medical history [55]. This includes the duration of the
diarrhea, constitutional and systemic symptoms, the presence
or severity of abdominal pain, and questions on the charac-
teristics of diarrhea (e.g., largeversus small volume; infrequent
or nocturnal versus frequent) to help localize the source to the
large or small intestine and narrow the differential diagnosis
(Fig. 2) [8, 55]. Classically, diarrhea from pathology in the
small intestine presents as voluminous and watery, occasion-
ally associatedwith weight loss as well as signs and symptoms
of malabsorption [59]. Bloating, nausea, and cramping may
also indicate a small intestine source. Diarrhea from the large
intestine is typically characterized by smaller, more frequent
bowel movements [48]. If there is inflammation of the rectum
and anus, patients may describe tenesmus and painful defe-
cation, whichmay be associatedwith hematochezia. A careful
review of medications, travel history, contact with ill indi-
viduals, recent ingestions, family history, surgical history, and
social history is important in evaluating acute and chronic di-
arrhea in the patient infected with HIV [8].
Physical examination and medical history of a patient
with HIV and diarrhea may help to evaluate the chronicity of
the diarrhea and the severity of illness and thereby focus the
differential diagnosis. Nutritional status should be assessed
by evaluating for bitemporal wasting, weight changes, skin
turgor, and mucosal dehydration. Basic vital signs and
orthostatic vital signs are essential to gauge the severity of
the patient’s illness and the degree of the patient’s volume
depletion. Documented fever may be an important clue of an
infectious etiology, though the absence of fever in an im-
munocompromised host does not rule out the possibility of
an infection. The GI examination may reveal tenderness to
palpation, possibly indicative of pancreatic pathology or
colitis. Hepatosplenomegaly may represent mycobacterial
infection, hepatitis, or fungal or malignant causes of diar-
rhea. A rectal examination is of integral importance because
it may reveal signs of sexually transmitted infections,
bleeding, tenderness, and masses, all of which may help to
establish a diagnosis. A careful, comprehensive examination
of the patient is essential to evaluate the severity of disease,
narrow the diagnosis, and guide the management.
Further diagnostic evaluation may also aid in a diagnosis
[8]. Laboratory tests should include comprehensive
metabolic panel, complete blood count with cell differential,
blood cultures, HIV viral load, and CD4? T cell count to
gauge the level of immune suppression. Stool examinations
should include fecal lactoferrin, fecal leukocytes, fecal cal-
protectin, fecal occult blood, and Clostridium difficile stool
culture, as well as three separate samples of ova and para-
sites. Infection with Cryptosporidium parvum is most com-
monly diagnosed by microscopic identification or enzyme
immunoassay of the organisms in the stool of patients but
can also be made by biopsy of the GI tract or aspiration from
the biliary tree during endoscopy. Diagnosis of Giardia can
be made by immunoassay of the stool but, again, can be
identified on endoscopic biopsy or on luminal aspiration
during endoscopy. Diagnosis of bacterial infections of the
GI tract, such as Salmonella, is made by stool culture.
If no pathogen is identified, further workup is needed
with an endoscopic examination [8]. Colonoscopy with
biopsy is necessary for diagnosis of CMV and HSV and
may reveal hemorrhage, colitis, and ulcers [46]. There is
some debate as to whether sigmoidoscopy or full colono-
scopy would be beneficial; one colonoscopy study
(n = 44) showed that nearly 40 % of 18 patients with
CMV-associated colitis had disease localized to the cecum
[60]. However, a prospective study comparing sigmoi-
doscopy and full colonoscopy showed that the sensitivity of
a sigmoidoscopy was 77 % for enteric pathogens and full
colonoscopy only yielded a small increase in sensitivity to
82 %, with no additional cases of CMV-associated colitis
identified [61]. Diagnosis of MAC infection within the GI
tract requires endoscopy, which may identify ulcerations,
erythema, or normal mucosa but may also reveal foamy
macrophages and positive culture via biopsy [45]. Diag-
nosis of fungal infections may be made histologically from
biopsies taken for endoscopy or colonoscopy [58]. Mucosal
biopsy can also help diagnose inflammatory bowel disease.
For patients with negative diagnostic results, the diagnosis
of noninfectious diarrhea can be made.
Treatment
The treatment of infectious diarrhea is outside the scope of
this article, and this section will focus on the treatment of
noninfectious diarrhea. If no other cause of diarrhea is
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identified, patient medications should be reviewed to
evaluate for an iatrogenic cause of the diarrhea. Pharma-
cologic options for the treatment of noninfectious diarrhea
in patients with HIV are primarily supportive. Hydration
via intravenous and oral routes, repletion of electrolytes,
and treating the underlying cause, if possible, are important
therapies for any patient with diarrhea [62]. Noninfectious
diarrhea can be managed by modifying ART and control-
ling symptoms with medications and lifestyle modification.
However, clinical guidelines for patients with HIV rec-
ommend careful evaluation of the symptoms and symp-
tomatic management of ART-related AEs (e.g., diarrhea)
before switching ART, with supportive care (e.g., an-
tidiarrheals) generally allowing for continuation of pre-
scribed ART therapy [63, 64]. However, cessation of ART
(‘‘drug holiday’’) is generally not advised as a management
strategy.
Antidiarrheal medications used in noninfectious diar-
rhea can be divided into several classes: adsorbents, anti-
motility agents, and antisecretory agents (Table 4) [8, 32,
62, 65–71]. Adsorbent drugs bind bacterial toxins, fluids,
and other compounds in the intestines to improve stool
consistency [65]. Drugs in this category include bismuth
subsalicylate, kaolin/pectin, and attapulgite (aluminum
magnesium silicate purified from clay). Data on the use of
adsorbents in patients with HIV are limited to one study in
which the efficacy of attapulgite was not better than
placebo in the management of diarrhea [65, 72].
Antimotility agents include loperamide, diphenoxylate/
atropine, and tincture of opium [65]. These agents act upon
opioid receptors in the gut to slow motility by decreasing
peristalsis and increasing tone in the large intestine. This
allows for greater fecal transit time and therefore longer
time for water absorption.
The antimotility agent diphenoxylate crosses the blood–
brain barrier and can cause central effects analogous to
other opioid agonists [62]. To prevent the abuse of diphe-
noxylate, it is usually sold as a combination agent with
atropine. Loperamide does not cross the blood–brain bar-
rier and does not have these adverse effects. One disad-
vantage to loperamide is that it may interact with ART
agents, such as ritonavir and saquinavir, which can limit its
use for long-term therapy [62, 67]. However, loperamide
has been shown in a small trial to decrease the number of
bowel movements in patients with protease inhibitor-in-
duced diarrhea [73]. The use of the combination of low-
dose diphenoxylate/atropine may be efficacious for treating
protease inhibitor-induced diarrhea; however, it appears
that this combination had no beneficial effect in patients
who were refractory to loperamide therapy [66]. Although
not studied for the treatment of diarrhea in patients with
HIV, tincture of opium is considered more effective than
loperamide as an antimotility agent, and it can be titrated
easily. Tincture of opium may be considered early in the
treatment algorithm for patients with severe HIV-associ-
ated diarrhea.
Fig. 2 General algorithm for
the diagnosis and management
of diarrhea in patients with HIV.
ART antiretroviral therapy, HIV
human immunodeficiency virus.
Reprinted with permission from
[8]
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Antisecretory agents, such as octreotide, racecadotril,
and crofelemer, directly inhibit secretory processes within
enterocytes [62, 68–71]. The mechanism of action of oc-
treotide, administered subcutaneously, is unclear, but it is
believed to alter the binding of vasoactive intestinal pep-
tide, therefore acting as an antimotility and antisecretory
agent [8, 62, 74]. Published data conflict about the efficacy
of octreotide in treating diarrhea in patients with AIDS [75,
76]. Oral racecadotril is an enkephalinase inhibitor, which
decreases the breakdown of endogenous gut opioids,
thereby decreasing the secretion of water and electrolytes
into the gut lumen [69]. Racecadotril is not currently
available in the USA.
Orally administered crofelemer is a dual inhibitor of
cAMP-stimulated cystic fibrosis transmembrane conduc-
tance regulator (CFTR) and calcium-stimulated calcium-
activated chloride channels (CaCC) in the gut [77]. Cro-
felemer is a minimally absorbed GI drug derived from the
latex of the Croton lechleri tree, and has reportedly been
used by Amazonian tribes for diarrheal relief [68]. Cro-
felemer is the only agent approved in the USA for the
symptomatic relief of noninfectious diarrhea in patients
with HIV on ART [78]. Compared with placebo, crofele-
mer has been shown, in a randomized, double-blind,
placebo-controlled trial with an open-label extension, to
significantly reduce symptoms of noninfectious diarrhea in
patients with HIV receiving ART (percentage of patients
with B2 watery stools per week for at least 2 of 4 weeks
during placebo-controlled phase: 17.6 versus 8.0 %, re-
spectively; P = 0.01) [70]. In addition, crofelemer has no
known drug interactions with ART drugs, is minimally
absorbed, and does not have a negative impact on the
clinical immune parameters (e.g., HIV viral load and
CD4? T cell counts) [68, 70, 71].
Conclusions
Diarrhea is a common complication of HIV infection that
has substantial clinical ramifications. The differential di-
agnosis for diarrhea in patients with HIV is broad. While
infection has historically been the major cause of diarrhea
in patients with HIV, with the widespread use of ART
therapy, noninfectious diarrhea has become a burden in this
population. Medications used for noninfectious diarrhea
include antimotility and antisecretory agents, including
crofelemer, which has been shown to significantly reduce
symptoms of noninfectious diarrhea. Improved treatment
of noninfectious diarrhea will likely improve HIV
medication adherence and quality of life.
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